We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Illumina, MolecularMD to Co-Develop Oncology Diagnostics
Read MoreHide Full Article
In a bid to expand its footprint in the multi-billion dollar cancer therapy market, Illumina, Inc. (ILMN - Free Report) has recently inked a co-development partnership with MolecularMD Corporation. MolecularMD offers molecular diagnostics solutions with focus on improving oncology medicines. Financial terms of the deal were, however, kept under wraps.
As per the terms of the agreement, Illumina and MolecularMD will co-develop and commercialize sequencing-based companion diagnostics to support biopharma drug development programs. These programs aim to offer advanced personalized medicines for oncology patients.
Notably, the collaboration will combine Illumina’s expertise in next-generation sequencing (NGS) technology with MolecularMD’s experience in developing precise, standardized molecular testing for new oncology drugs, and their subsequent FDA submissions.
After opening the advanced diagnostic laboratory in Cambridge, MA in 2012 to support clinical trials of NGS solutions-based oncology drug programs, MolecularMD has been deploying NGS diagnostics for a broad range of drug targets and indications. We believe the latest partnership will ramp up the demand for Illumina’s NGS solutions for developing tests under clinical trials supported by MolcularMD.
Interestingly, Illumina has been pursuing strategic partnerships with therapeutic and diagnostic services providers in order to expand its business. As an instance, in recent past, the company had become actively involved in the Chinese precision medicine program for sequencing millions of genomes. It has also undertaken the AstraZeneca project to access 2 million genomes.
These numbers, however, reflect only a small fraction of the sequencing capacity required to fulfill the growing demand for population sequencing programs. This indicates immense room for growth of Illumina’s products, which will boost its profit margins.
Further, to establish itself in the cancer therapeutic space, Illumina created a new company, Grail, which focuses on early cancer detection and aims to reduce global cancer mortality. With Grail, Illumina has been preparing to initiate a large-scale clinical trial in 2017 to demonstrate a stage shift in cancer diagnosis.
Cancer is a deadly disease, which is affecting more and more people every day. We believe that such partnerships will play a crucial role in increasing Illumina’s shares in the global cancer therapeutic market.
Illumina currently carries a Zacks Rank #4 (Sell). Better-ranked medical stocks include Boston Scientific Corporation (BSX - Free Report) , ICU Medical, Inc. (ICUI - Free Report) and LeMaitre Vascular, Inc. (LMAT - Free Report) . All these stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Illumina, MolecularMD to Co-Develop Oncology Diagnostics
In a bid to expand its footprint in the multi-billion dollar cancer therapy market, Illumina, Inc. (ILMN - Free Report) has recently inked a co-development partnership with MolecularMD Corporation. MolecularMD offers molecular diagnostics solutions with focus on improving oncology medicines. Financial terms of the deal were, however, kept under wraps.
As per the terms of the agreement, Illumina and MolecularMD will co-develop and commercialize sequencing-based companion diagnostics to support biopharma drug development programs. These programs aim to offer advanced personalized medicines for oncology patients.
Notably, the collaboration will combine Illumina’s expertise in next-generation sequencing (NGS) technology with MolecularMD’s experience in developing precise, standardized molecular testing for new oncology drugs, and their subsequent FDA submissions.
After opening the advanced diagnostic laboratory in Cambridge, MA in 2012 to support clinical trials of NGS solutions-based oncology drug programs, MolecularMD has been deploying NGS diagnostics for a broad range of drug targets and indications. We believe the latest partnership will ramp up the demand for Illumina’s NGS solutions for developing tests under clinical trials supported by MolcularMD.
Interestingly, Illumina has been pursuing strategic partnerships with therapeutic and diagnostic services providers in order to expand its business. As an instance, in recent past, the company had become actively involved in the Chinese precision medicine program for sequencing millions of genomes. It has also undertaken the AstraZeneca project to access 2 million genomes.
These numbers, however, reflect only a small fraction of the sequencing capacity required to fulfill the growing demand for population sequencing programs. This indicates immense room for growth of Illumina’s products, which will boost its profit margins.
Further, to establish itself in the cancer therapeutic space, Illumina created a new company, Grail, which focuses on early cancer detection and aims to reduce global cancer mortality. With Grail, Illumina has been preparing to initiate a large-scale clinical trial in 2017 to demonstrate a stage shift in cancer diagnosis.
Cancer is a deadly disease, which is affecting more and more people every day. We believe that such partnerships will play a crucial role in increasing Illumina’s shares in the global cancer therapeutic market.
Illumina currently carries a Zacks Rank #4 (Sell). Better-ranked medical stocks include Boston Scientific Corporation (BSX - Free Report) , ICU Medical, Inc. (ICUI - Free Report) and LeMaitre Vascular, Inc. (LMAT - Free Report) . All these stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>